These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 23503338)

  • 1. Intravitreal bevacizumab for juxtafoveal choroidal neovascularization secondary to multifocal choroiditis.
    Parodi MB; Iacono P; Mansour A; Benedetto Ud; Knutsson KA; Bandello F; Ziemssen F; Ness T; Dodwell D
    Retina; 2013 May; 33(5):953-6. PubMed ID: 23503338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal bevacizumab for extrafoveal choroidal neovascularization secondary to pathologic myopia.
    Parodi MB; Iacono P; Papayannis A; Kontadakis S; Cascavilla ML; Zucchiatti I; Bandello F
    Retina; 2013 Mar; 33(3):593-7. PubMed ID: 23190919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
    Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
    Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal bevacizumab for choroidal neovascularisation in serpiginous choroiditis.
    Parodi MB; Iacono P; La Spina C; Knutsson KA; Mansour A; Arevalo JF; Bandello F
    Br J Ophthalmol; 2014 Apr; 98(4):519-22. PubMed ID: 24414400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal bevacizumab as primary treatment of choroidal neovascularization secondary to punctate inner choroidopathy: results of a 1-year prospective trial.
    Zhang H; Liu ZL; Sun P; Gu F
    Retina; 2012 Jun; 32(6):1106-13. PubMed ID: 22481479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
    Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
    Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multifocal electroretinography and optical coherence tomography changes after repeated intravitreal bevacizumab (Avastin) in myopic choroidal neovascularization.
    Sabry D; Gad MA; Enam KM
    Retina; 2013 Mar; 33(3):598-605. PubMed ID: 23064427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis.
    Parodi MB; Iacono P; Kontadakis DS; Zucchiatti I; Cascavilla ML; Bandello F
    Arch Ophthalmol; 2010 Sep; 128(9):1100-3. PubMed ID: 20837791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab for inflammatory choroidal neovascularization: results from the Pan-American Collaborative Retina Study Group at 24 months.
    Arevalo JF; Adan A; Berrocal MH; Espinoza JV; Maia M; Wu L; Roca JA; Quiroz-Mercado H; Ruiz-Moreno JM; Serrano MA;
    Retina; 2011 Feb; 31(2):353-63. PubMed ID: 20890239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
    Chan WM; Lai TY; Liu DT; Lam DS
    Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization.
    Ruiz-Moreno JM; Montero JA; Arias L; Araiz J; Gomez-Ulla F; Silva R; Piñero DP
    Retina; 2010; 30(10):1609-15. PubMed ID: 20856171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal bevacizumab for nonsubfoveal choroidal neovascularization associated with angioid streaks.
    Battaglia Parodi M; Iacono P; La Spina C; Berchicci L; Scotti F; Leys A; Introini U; Bandello F
    Am J Ophthalmol; 2014 Feb; 157(2):374-377.e2. PubMed ID: 24211865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal ranibizumab for pigment epithelium detachment with subfoveal occult choroidal neovascularization: a prospective 24-month case series.
    Parodi MB; Iacono P; Papayannis A; Kontadakis SD; Cascavilla M; Pierro L; Gagliardi M; Bandello F
    Am J Ophthalmol; 2013 Jan; 155(1):103-108.e2. PubMed ID: 23022164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macular functional changes evaluated with MP-1 microperimetry after intravitreal bevacizumab for subfoveal myopic choroidal neovascularization: one-year results.
    Scupola A; Tiberti AC; Sasso P; Savastano MC; Mastrocola A; Marangoni D; Minnella AM; Falsini B; Balestrazzi E
    Retina; 2010 May; 30(5):739-47. PubMed ID: 20038860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year visual and anatomic results of administrating intravitreal bevacizumab in inflammatory ocular neovascularization.
    Mansour AM; Arevalo JF; Fardeau C; Hrisomalos EN; Chan WM; Lai TY; Ziemssen F; Ness T; Sibai AM; Mackensen F; Wolf A; Hrisomalos N; Heiligenhaus A; Spital G; Jo Y; Gomi F; Ikuno Y; Akesbi J; LeHoang P; Adan A; Mahendradas P; Khairallah M; Guthoff R; Ghandour B; Küçükerdönmez C; Kurup SK
    Can J Ophthalmol; 2012 Jun; 47(3):269-74. PubMed ID: 22687305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization.
    Inoue M; Kadonosono K; Watanabe Y; Sato S; Kobayashi S; Yamane S; Ito R; Arakawa A
    Retina; 2010 May; 30(5):733-8. PubMed ID: 20168271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.
    Zhang H; Liu ZL; Sun P; Gu F
    Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional recovery after intravitreal bevacizumab treatments for idiopathic choroidal neovascularization in young adults.
    Wang F; Wang W; Yu S; Wang W; Lu F; Xu F; Hu W; Jiang Y; Wu Y; Wang H; Xu X; Sun X
    Retina; 2012 Apr; 32(4):679-86. PubMed ID: 22105501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.